Clinical trial · Observational
Non-Invasive ctDNA Methylation Detection for Lung Nodule Patients
Detection of Early-stage Lung Cancer by Using Methylation Signatures in Circulating Tumor DNA
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Low-dose computed tomography (LDCT) is recommended for early-stage lung cancer screening. However, it is often difficult to determine indolent lesions from more aggressive tumors without an invasive intervention or prolonged follow-up period. Thus, the main purpose of this study is to develop a non-invasive method to detect lung-cancer specific circulating tumor DNA (ctDNA) in blood, which can greatly improve the specificity of lung cancer early screening.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Lung Nodule | — | UNRESOLVED | — |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (2)
- label
- Lung nodule group
- label
- Healthy Control group
Primary outcomes (1)
- measure
- Noninvasive assisted diagnosis of benign and malignant pulmonary nodules
- timeFrame
- 1 year
- description
- The biomarker classification model can be used to differentiate patients, who had positive LDCT results, with benign or malignant lung nodules.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. 18 years old or above with pulmonary nodule(s) found by LDCT, mean diameter below 30mm. 2. The nodule lesion is peripheral, no signs of lymphatic infiltration or distal metastasis. 3. Fit and consent to surgical resection. 4. Agree to participate in this study and sign informed consents. Exclusion Criteria: 1. Fail to understand or agree to sign informed consent. 2. Patients who did not follow the test plan for timely blood collection or did not cooperate with the study follow-up work. 3. Patients with previous history of cancer and/or cancer treatment such as surgery, radiotherapy, chemotherapy or targeted therapy. 4. Failing to meet the requirements for blood sampling.
References
Publications (0)
Data not yet available